Liver disease-significant improvement with lamivudine

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis B virus (HBV) infection exhibits variable natural history, impacting life expectancy.
• Liver histology is crucial for assessing disease progression in chronic hepatitis B.
• Lamivudine is an oral nucleoside analogue investigated for HBV treatment.

Purpose of the Study:

• To evaluate the efficacy of lamivudine in improving liver histology and disease markers in chronic hepatitis B.
• To assess the impact of lamivudine on fibrosis progression, cirrhosis development, and viral suppression.

Main Methods:

• Phase III clinical trials involving oral lamivudine (100 mg/day) in chronic hepatitis B patients.
• Assessment of liver histology using the Knodell histological activity index (HAI).
• Monitoring of alanine transaminase (ALT) normalization, hepatitis B e antigen (HBeAg) seroconversion, and serum HBV DNA levels.

Main Results:

• Lamivudine therapy led to significant improvements in Knodell HAI scores, with greater benefits after 2 years.
• Histological data indicated resolution or reduction in fibrosis progression and decreased progression to cirrhosis.
• Significant enhancement of HBeAg seroconversion and rapid suppression of HBV DNA (viremia) were observed.
• Emergence of YMDD motif variants did not significantly worsen the Knodell HAI score.

Conclusions:

• Lamivudine is the first oral antiviral for chronic hepatitis B, effectively reducing liver disease severity and cirrhosis progression.
• The drug is well-tolerated, presenting a viable therapeutic option to improve patient prognosis.
• Lamivudine demonstrates significant benefits in histological improvement, viral suppression, and seroconversion.